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Abstract
Background: Variety of information relating between genome and the pathological findings in disease will yield a
wealth of clues to discover new function, the role of genes and pathways, and future medicine. In addition to
molecular information such as gene expression and genome copy number, detailed clinical information is essential
for such systematic omics analysis.
Results: In order to provide a basic platform to realize a future medicine based on the integration of molecular
and clinico-pathological information of disease, we have developed an integrated clinical omics database (iCOD) in
which comprehensive disease information of the patients is collected, including not only molecular omics data
such as CGH (Comparative Genomic Hybridization) and gene expression profiles but also comprehensive clinical
information such as clinical manifestations, medical images (CT, X-ray, ultrasounds, etc), laboratory tests, drug
histories, pathological findings and even life-style/environmental information. The iCOD is developed to combine
the molecular and clinico-pathological information of the patients to provide the holistic understanding of the
disease. Furthermore, we developed several kinds of integrated view maps of disease in the iCOD, which
summarize the comprehensive patient data to provide the information for the interrelation between the molecular
omics data and clinico-pathological findings as well as estimation for the disease pathways, such as three layer-
linked disease map, disease pathway map, and pathome-genome map.
Conclusions: With these utilities, our iCOD aims to contribute to provide the omics basis of the disease as well as
to promote the pathway-directed disease view. The iCOD database is available online, containing 140 patient cases
of hepatocellular carcinoma, with raw data of each case as supplemental data set to download. The iCOD and
supplemental data can be accessed at
http://omics.tmd.ac.jp/icod_pub_eng
Background
Recent rapid advances in the human genomics and the
subsequent “post-genomic” comprehensive molecular
information collectively called “omics” [1,2], such as
transcriptome, proteome, metabolome, are bringing
about a new possibility of medicine. Such application of
molecular information to medicine has been so far
called genomic medicine [3], where “personalized medi-
cal care” is aimed to be realized based on the inborn
individual genomic differences or polymorphisms.
Recently, however, post-genomic omics information, for
example, gene expression profile (transcriptome) or cel-
lular protein mass spectrometry (proteome) of diseased
tissues has been found to be much more directly related
to patient’s disease states; it is site-specific in the dis-
eased area and changes through the progression of the
disease, so that it can bring about more exact predictive
information about the ongoing disease process.
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ogy in the biological science, also in disease study, needs
for the systems approach to understand a disease as an
integrated whole have been widely recognized. Except
for rare monogenetic diseases, most of the diseases can
be considered as an integrated system where aberrations
of molecular, tissue/organic and individual level are clo-
sely interrelated to produce clinical phenotype. We call
this perspective “systems pathology” view of disease [4]
With these backgrounds, it becomes accepted that the
interrelation between various omics information and
clinico-pathological findings of disease is of crucial
importance to be clarified in order to develop a new
possibility of medicine, which we call “omics-based sys-
tems medicine”.
Cancer is now considered as systems dysfunction of
cellular regulatory pathway which is caused by the com-
bined effects of environmental/life-style related factor
and genetic aberration such as somatic or germline
mutations, SNPs, copy number alternation, epigenetic
changes and so forth. For diagnosis and therapy of such
diseases, not only the molecular information but also
clinical, pathological and life-style information is indis-
pensable. Without them, complex diseases such as can-
cer will not be able to be examined correctly [5-8].
There have been developed many cancer databases
[9-11], each of which stores a variety of molecular infor-
mation. However, more detailed clinical/environmental
information in combination with the molecular informa-
tion is needed to elucidate the whole process of the
complex diseases such as cancer. We have first devel-
oped an integrated clinical omics database (iCOD), a
basic platform where comprehensive disease information
of the patient is collected. This database includes not
only molecular omics data such as CGH (Comparative
Genomic Hybridization) and gene expression profiles
but also comprehensive clinical information such as
clinical manifestations, medical images (CT, X-ray, ultra-
sounds, etc), laboratory tests, drug histories, pathological
findings and even life-style/environmental information,
and gene search menu, related to these clinical informa-
tion. Furthermore, we developed several kinds of inte-
grated view maps of disease in our iCOD, which
summarize the comprehensive patient data to provide
the information for the interrelation between the mole-
cular omics data and clinico-pathological findings as
well as estimation for the disease pathway, such as three
layer-linked disease map, disease pathway map, and
pathome-genome map. With these utilities, our iCOD
aims to clarify the omics basis of the disease as well as
to promote the pathway-directed disease view.
Recently, some pharmaceutical companies announced
that they will open the genomic data focus on lung and
gastric cancers to rapidly increase knowledge of disease
and disease process. So, we can expect that the field of
research based on such clinical/environmental informa-
tion will develop with our iCOD.
Related work
Cancer Genome Anatomy Project (CGAP) [9]), The
Cancer Genome Atlas (TCGA) [10], Cancer Genome
Project (CGP) (http://www.sanger.ac.uk/genetics/CGP/)
and Atlas of Genetics and Cytogenetics in Oncology and
Haematology (AGCOH) [11] are related to our work.
However, clinical information is usually only partially
treated as Tissue information.
Construction and content
Content
The contents of the iCOD are based on clinical, patholo-
gical, and environmental data obtained from patients
who received medical care at Tokyo Medical and Dental
University Hospital and other collaborating institutions
since 2005. At present, we focus on cancer patients. With
the tight collaboration with our University hospital, we
have collected hepatocellular carcinoma, colon cancer,
and oral cancer samples. Samples were collected just
after surgery, and were snap-frozen in liquid nitrogen.
Meanwhile, clinical research coordinator (CRC) obtained
comprehensive clinical records, laboratory data, patholo-
gical findings, diagnosis and prognosis, and also per-
formed interview to collect extensive information on
medical history, lifestyle and so on. The collected infor-
mation items are shown in figure 1. A written informed
consent was obtained from each patient, and our institu-
tional review board (IRB) approved our iCOD project.
Personal information and related items were anonymized
and stored in the database.
We also collected gene expression data, array CGH
data with detailed pathological information of the sam-
ple tissue obtained from each patient. DNA and RNA
were extracted from the surgical specimen, after laser
capture microdissection which was conducted if
required. All of the expression data in the database was
obtained using Affymetrix HG-U133 plus 2.0 array as
described previously [13]. Array CGH analysis was per-
formed as described in [14]. We have so far collected
comprehensive information about several kinds of can-
cer such as hepatocellular carcinoma, colon and oral
cancer of more than 500 cases for its domestic version,
of which internationally publicized database is now
available online, containing 140 patient cases of hepato-
cellular carcinoma, which can be browsed at “Case
Archive” section in database.
Implementation
The iCOD was made on the PostgreSQL Database sys-
tem. This database is capable of storing and handling
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layered (2D-3L) map. The 2D-3L program script is run-
ning on the Apache-Tomcat web server.
The back end data analysis programs were written by
Java-servlet R statistical software which are available
upon request.
Utility and discussion
Figure 2 shows the key screenshot of our iCOD data-
base. iCOD database has two different sections. One is
“Case Archive”. The user can browse the patient data by
directly viewing the case list or search for the patients
having several specific features by use of retrieval func-
tion in the section. Another section is “Clinical Omics
Data Analysis”. In this section, various kinds of analyti-
cal results about the interrelation between clinico-patho-
logical findings and molecular omics or estimation of
disease pathways can be seen through the web interface.
Viewing and searching the case in the database
The user can browse the patient list in the database by
clicking “Display all case List” in the section of “Case
Archive”. To see the details of specific cases, click
“Show case information” button. The user will be able
to examine further data of an individual patient such as
clinical manifestations, medical images (CT, X-ray, ultra-
sounds, etc), laboratory tests, drug histories, and patho-
logical findings as well as life style information. The
case information items and their layered structures are
listed in figure 1. The time axis diagram shows the
kinds of data stored and their collected dates of each
patient in detail (see figure 3).
The iCOD provides users a convenient search engine
to query keyword related to pathological/clinical find-
ings and patient ID stored in the database. To search
the individual patient cases in the database satisfying the
conditions, enter key terms of the query in the “Search”
box in the section “Case Archive”.
Clinical omics data analysis
“Clinical omics data analysis” provides various maps to
observe the interrelation (correlation) between clinico-
pathological phenotype and gene expression using mul-
tivariate statistical analysis applied to the molecular and
clinico-pathological information of the patients.
Click on the “Clinical Omics Data Analysis” button
from the top page. The user will be able to choose two
different analysis methods, which are 2 dimensional 3
layered (2D-3L) map and Pathome-Genome map (CCA).
The 2D-3L map consists of two types of views. The
left side view shows the overview of the plot of each
patient which provides the relative position of the
patient’s information in each of the molecular, patholo-
gical and clinical layer. For each layer, principal
component analysis (PCA) is used to create 2D map by
summarizing the multivariate data into the first and the
second principal component scores. The right side view
shows the detailed data list in the each layer of the
selected patients. Molecular layer displays the result of
gene expression profile by a heatmap diagram. In this
Figure 1 Collected data items and their hierarchical structure.
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selected in the “Parameter Settings” diagram.
The screenshot in the figure 4 displays the heatmap in
which the criterion of existence or non-existence of
“Portal vein/Hepatic vein invasion” is used to extract the
differentially expressed genes; the most significant differ-
entially expressed 100 genes are extracted by the
user-specified criteria of p-value of Wilcoxon rank-sum
test (see figure 5).
In pathological layer and clinical layer, each plot
represents patient position in the corresponding 2 prin-
cipal components coordinate system. By selecting a
patient in a certain layer, the 2D-3L map draws con-
necting line between corresponding points of different
layers of the same patient, by which the user can intui-
tively understand the relationship among different layers
of an individual patient. The user can choose multiple
p a t i e n tp o i n t sa tt h es a m etime, and the selected
patients are shown in the data list; this can be operated
by specifying the region including the entire designated
patient in the layer with a simple mouse operation.
This map has a parameter setting function for a custo-
mized analysis. To use this function, the user only have
to change detailed parameter values in three buttons
“Data selection”, “Parameter setting” and “Display set-
ting” at the head of the 2D-3L map page. In “Data selec-
tion” page, select the type of cancer you wish to analyze
(only “Hepatocellular carcinoma” dataset is currently
Figure 2 Key screenshot of the iCOD database system.
Figure 3 Time Axis Diagram of data collection history of each
patient. Time Axis Diagram shows time series of medical events of
each patient. Each point means date when the data collection was
performed. Collected information can be seen by clicking each
point in the diagram.
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cer datasets in preparation). In “Parameter setting” page,
the user will be able to specify the any group of clinical/
pathological items to be applied by principle component
analysis to determine layer axis.In “Display setting” page,
shapes and colours can be adjusted in accordance with
various parameters; so that characteristics of a specific
group of patients can be obtained by changing these fac-
tors for comparison.
Figure 4 shows the case study of the 2D-3L map. First,
we can obtain overexpressed or suppressed gene list
corresponding to the criterion “Portal vein/Hepatic vein
invasion” from the molecular layer. In this case, we
found MCM6 gene, DNA replication licensing factor.
We are also able to confirm the relation between
patient’s recurrence and the size of tumor, correspond-
ing to the above-mentioned criterion. Please look at the
explanation of figure 4.
Pathome-Genome map shows the relation between
clinical/pathological information and gene expression,
which was calculated by the regularized canonical corre-
lation analysis (CCA) method (figure 6(a)). CCA is a
generalized version of multiple regression analysis, and
the associations between two groups of variables are
obtained by maximizing the correlation coefficient
between the linear combination of each group of vari-
ables. In Pathome-Genome map, CCA is used to analyze
and visualize the correlation structure between clinico-
pathological factors and genes. So, the user can under-
stand the interrelation between two different kinds of
data in a same two dimensional coordinates. As
described in previous paragraph, the user can arbitrary
select the type of cancer and specify the clinical/patho-
logical items he wish to analyze. In this case, we exam-
ined what genes are related for a certain clinical items
Figure 4 2 Dimensional 3 Layered map. Two dimensional three layered map, composed of molecular, pathological and clinical layer map,
shows the relative position of the patient within each layer and interrelation between the position of different layer. As shown in this figure, the
user can intuitively understand the relation among gene expression pattern (molecular state), pathological state and clinical state of the patient.
The axes of the pathological or clinical layer are the first and the second principal component extracted from the principal component analysis
applied to the user-specified group of pathological or clinical items, respectively. (a) In the molecular layer, overexpressed genes are chosen,
corresponding to the criterion “Portal vein/Hepatic vein invasion +”. We can find MCM6 gene, DNA replication licensing factor in the
overexpressed genes. On the other hand, pathological layer shows that larger tumors are found (see x-axis of pathological layer) from among
this group. Lines between pathological layer and clinical layer show that “incipient” cases (x-axis in clinical layer) usually have larger tumors. (b)
Parameter settings, used to draw the map. This system can use the axis specified by the user. In clinical layer, x-axis is recurrence, y-axis is AFP
(tumor markers for detection of hepatocellular carcinoma). In pathological layer, x-axis is “Portal vein/Hepatic vein invasion”, y-axis is “Maximum
Diameter”.
Figure 5 Gene selection depicted on the heatmap. The criterion
to extract the differentially expressed genes and the number of
genes depicted on the heatmap can be specified by the user
through the “Parameter setting” page. Genes are extracted by the
user-specified criteria of p-value of Wilcoxon rank-sum test.
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i n v a s i o n ,a n dT N M ) .F i g u r e6 ( a )c l e a r l ys h o w st h er e l a -
tion between Portal vein/Hepatic vain invasion and cell
cycle related genes (CCNA2/B1, MAPK13, BUB, and
CDC2).
Future development
Our international version is available now, containing
140 patient cases of hepatocellular carcinoma. The num-
ber of cases are increasing and containing the other dis-
ease cases such as colon and oral cancer. We also plan
to prepare retrieval page that displays the correspon-
dence table of arbitrary gene and its p-values of all cri-
terions used in this data base. We are preparing to
accept clinical omics data from other public projects as
a repository. We are also preparing to disclose our web
based analysis tool for microarray called “Microarray
Analysis Workflow”, used to build our database.
Conclusions
Many cancer related databases which stored a variety of
molecular information have been developed, as described
before. However, more detailed clinical/environmental
information in combination with the molecular information
is needed to elucidate the whole process of the complex
diseases such as cancer. From this point of view, our
iCOD is the first database which provides the compre-
hensive clinical, pathological and life-style information in
addition to the molecular biological information as well
as their estimated interrelation. The iCOD database is
useful both for clinical researchers who intend to have
knowledge about molecular basis of disease which could
be used for diagnosis, therapy and prognosis of the dis-
eases, and for molecular biologists who intend to know
the function and phenotype of the molecular pathways
and their interrelation through the knowledge in the
cases of their dysfunction. Our subproject aims to
develop the model disease database in the “omics” era
which has a standardized database organization being
able to cover the multi-hierarchical (from molecular to
clinical level) information concerning the diseases.
Availability and requirements
We prepared the download page of raw gene expression
data for users who want to analyze them with his/her
own tool. The supplemental data can be found at http://
omics.tmd.ac.jp/icod_pub_eng/download. Raw data files
consist of raw gene expression data by Affymetrix .CEL
Figure 6 Pathome-Genome map. The result of the canonical correlation analysis applied to clinico-pathological findings and gene expression
profile. By using this map, the relation between genes and clinical/pathological findings is easily understood. (a) Genes and clinico-pathological
findings at the closer position in the map mean that they have higher correlation each other. The enlarged view shows that upregulation of cell
cycle-associated genes such as cyclin family CCNA2/B1, MAPK13, BUB, and CDC2, enclosed by blue rectangles, significantly correlated with Portal
vein/Hepatic vain invasion, enclosed by green rectangles. This factor is directly associated with well-established clinical criteria such as TNM stage
(IVA). (b) Parameter settings, used to draw the map.
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case is stored by CSV text format.
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